Tuesday, August 18, 2009

Chemotherapy Safety at Home



Of course, anyone using or dispensing chemotherapy in their clinic needs to follow basic safety precautions to protect their patients and their staff. However, practicing chemotherapy safety doesn't end at the clinic door. Clients need to be informed of the potential risks of handling oral chemotherapy and/or the risks of handling the wastes of a patient who has had chemotherapy after they leave the clinic. You should have a very rigid protocol in place for in house and at home chemotherapy handling before ever considering using and handling chemotherapy. We make the following recommendations to clients:

Handling Waste

Most chemotherapeutic agents are eliminated in the feces or urine. In most cases, the drugs are eliminated in a changed form that poses little risk. However, pets should be walked and allowed to urinate or defecate outside your children’s play area for 48 hours after your pet’s last treatment.
Disposable latex gloves should be used to clean up any urine, stool or vomit for 48 hours after your pet’s last treatment. Place soiled paper towels and gloves in a sealed plastic container to dispose of.
For cats, clean litter box frequently. Remove feces and flush down the toilet. Dispose of litter in a sealed plastic container.
Contaminated bedding should be washed separately from other laundry.
Clients who are pregnant, breastfeeding, trying to conceive, immune suppressed or taking immunosuppressive drugs should avoid their pet’s waste for 48 hours following treatment.

Handling Chemotherapy Drugs

Wear latex gloves when handling oral chemotherapy medications at home. Wash hands immediately and thoroughly after handling medication. Gloves may be resealed and returned to the clinic for disposal.
Never break or crush chemotherapy tablets.
Do not store chemotherapy medication near food, cosmetics, or other medications. Keep out of the reach of children and pets
If you come in contact with chemotherapy medication, wash the area immediately with soap and water. If exposed skin becomes irritated and does not quickly resolve, contact your physician.
Wash any surfaces, such as counter tops or floors that may have come in contact with the chemotherapy medication with a rubbing alcohol wipe followed by soap and water, then wipe dry with a paper towel.

For more information, please contact us at 734-459-6040.

Monday, August 17, 2009

Happy Monday!

Instead of posting pictures of the little Chihuahua ("Stevie") on the blog, it's better to go to our website www.veterinarycancer.com and view the video! Little Stevie is doing great post-operatively and was adopted by my mother and dad!! He's enjoying the love and attention and every day becomes more lovable.

Exploring better options: Chemotherapy protocols for diseases such as lymphoma and osteosarcoma have not changed significantly in over 20 years, nor have the median survival times despite the addition of new drugs. In an attempt to investigate new ways of giving chemotherapy, we are now routinely using metronomic (low dose) chemotherapy for a variety of tumors at ACIC, including hemangiosarcoma and osteosarcoma.

What exactly is metronomic chemotherapy?

“The definition of metronomic chemotherapy varies, but generally it refers to repetitive, low doses of chemotherapy drugs designed to minimize toxicity and target the endothelium or tumor stroma as opposed to targeting the tumor.” ...Dr. Harold Burstein of the Dana-Farber Cancer Institute.

An excellent basic description of metronomic chemotherapy comes from Dr. Robert S. Kerbel, one of the leaders in this field of metastasis and anti-angiogenesis who is highly regarded for discoveries that are helping to improve cancer therapies and the quality of life of cancer patients:

For almost half a century, systemic therapy of cancer has been dominated by the use of cytotoxic chemotherapeutics. Most of these drugs are DNA-damaging agents that are designed to inhibit or kill rapidly dividing cells. They are often administered in single doses or short courses of therapy at the highest possible dosage without causing life-threatening levels of toxicity. This is referred to as the “Maximum Tolerated Dose” (MTD). MTD therapy requires prolonged breaks (generally 2-3 weeks in duration) between successive cycles of therapy. Progress had been modest in terms of curing or significantly prolonging the lives of patients with cancer using MTD—particularly those with advanced-stage or metastatic disease. The higher the dosage of chemotherapy, the more likely we are to kill the cancer, but the limiting factor is always the adverse side effects that occur with increasing dosages. More recently, a lot of research has been directed towards a reappraisal of the best ways of administering chemotherapy. Instead of using short bursts of toxic MTD chemotherapy interspersed with long breaks to allow recovery from the harmful side effects, there is now a shift in thinking towards the view that more compressed or accelerated schedules of drug administration using much smaller dosages than MTD might be more effective—not only in terms of reducing certain toxicities but perhaps even improving antitumor effects as well.” (Kerbel RS and Kamen BA, The Anti-Angiogenic Basis of Metronomic Chemotherapy, Nature Reviews Cancer 2004.)

In dogs and cats, we utilize chemotherapy agents such as cyclophosphamide at dosages approximately one-tenth of standard MTD dosages. These drugs are given daily to every other day. We have been using metronomic therapy for over 2 years and have experienced negligible side effects. Metronomic chemotherapy appears to be as effective as MTD (Adriamycin in this case) in dogs treated for hemangiosarcoma. Studies have also shown that metronomic chemotherapy may be effective in delaying recurrence of incompletely excised soft tissue sarcomas (STS). Of course, more aggressive surgery or radiation therapy is most effective in the setting of incompletely excised STS, but metronomic chemotherapy could provide a reasonable alternative for pet owners who cannot afford surgery or radiation.

Wednesday, August 12, 2009

Hoping to make a difference!

Yesterday, Dr. Walshaw performed a premaxillectomy on one of the sweet Chihuahua's rescued from that horrible scene in Dearborn where over a hundred live dogs were found in a home along with over a hundred that had died. This little 7-10 year old male Chihuahua, named Stevie, was found to have a tumor on the rostral (front) part of the maxilla which was protruding under the lip. Today, he looks great! He's still having to be encouraged to eat but is expected to make a full recovery. Although biopsy and margin reports are still pending, our suspicion is either benign epulis or low grade malignancy. Treatment, hopefully, will be curative. Without this surgery, the mass would have continued to grow and destroy the architecture of his maxilla, become ulcerated and bleed, and cause great difficulty in eating. Without surgery, adoption would have been difficult. This type of surgery typically costs between $2500-3500, but in order to join the overwhelming effort to help these poor dogs, our hospital donated these services so that Stevie will be able to find a "forever" home disease-free and pain-free. Steve's foster mom said that he just recently barked for the first time and didn't know what grass was when she put him down on her lawn. I'll keep you updated on the biopsy results and Stevie's progress and will add pictures soon!

Monday, August 10, 2009

Monday's hint for the day!

The information/results that your pathologist gives you is only as good as the sample and information you provide. Don't just cut a "representative" sample, be sure to send the sample in it's entirety if possible (obviously some limitations exist such as those 10 pound splenic tumors!). Mark your margins with India Ink or suture material to help orient the pathologist, as tumors shrink and distort in formalin on their way to the lab. If you do have a larger size tumor, you can "bread loaf" cut it, leaving the base in tact so that the formalin will fix the tissue, but it stays in it's original configuration. Give a good, complete clinical history.

Most importantly, develop a close relationship with your pathologist! If the diagnosis doesn't fit the clinical picture, call and find out why. The basic information need with each histologic cancer diagnosis should be 1.) what is it 2.) did I get it all (margins) 3.) how wide the microscopic margins are 3.) indication of biologic behavior (poorly differentiated, etc.). Don't forget to ask regarding immunohistochemistry stains if the diagnosis is not clear with routine H and E staining.

Most clinicians identify a pathologist that is more experienced in certain areas (e.g. a pathologist that is more experienced in dermatology or one more experienced in cancer) when submitting a sample. Never be afraid to call your pathologist and ask for a re-read if all the information listed above is not provided for you. Some labs charge more for a more detailed report, but you really need a more detailed report to decide if post-operative cancer treatment is necessary.

Friday, August 7, 2009

Good morning!

We currently have 3 clinical trials up and running successfully! Significant financial assistance for diagnosis and treatment is provided for clients whose pets enter the clinical trial. Eligible patients include those with transitional cell carcinoma, metastatic osteosarcoma, and lymphoma. Please contact our office for more information. Phone consultations are available but are limited to referring veterinarians only. If your pet is diagnosed or suspected to have one of these cancers, contact your primary care veterinarian and have him/her call us for more details about our clinical trials.

Hint for the day: Therapy for transitional cell carcinoma (TCC) of the bladder is usually limited to non-surgical therapies. TCC is rarely amenable to complete surgical excision due to the location within the bladder and also it's infiltrative nature along the bladder wall. Therefore, if clinical symptoms are suggestive of bladder cancer, an ultrasound should be done prior to any surgical intervention. If a lesion consistent with cancer is evident, a diagnosis should be attempted through non-surgical means. I have seen many cases over the years that have come to me after a surgical diagnosis of TCC with disease transplanted to the surgical incision line. This occurs because instruments used to operate on the bladder were also used to close the abdominal wall incision. Surgery should be reserved for patients whose tumors are in locations of the bladder that would suggest a non-TCC tumor. Routine cystocentesis should also be avoided if patients are known to have TCC.

Wednesday, August 5, 2009

Welcome to the Animal Cancer and Imaging Center's new blog!

This blog is designed to provide a resource on animal cancer for veterinarians and pet owners. There are thousands and thousands of publications, articles, book chapters, etc. on veterinary oncology topics available to the knowledgeable reader. But new information is constantly evolving and by the time publications get to print, they are already on the road to being outdated. Some of the most valuable and up to date information is gained from all of those countless patients whose cases are never published. In short, experience is an important resource and reference that shouldn't be overlooked.

I want to share our experience with you in hopes of helping your patients or your own pets whose circumstances may be similar to patients we have already treated. My intense oncology experience began in 1988 at the beginning of my medical oncology residency at Colorado State University. I became board certified in 1992. It has now been 21 years since I have practiced oncology exclusively. We also have the valuable resource of Dr. Richard Walshaw, board certified surgeon, member of the prestigious Veterinary Society of Surgical Oncology, and professor emeritus, MSU College of Veterinary Medicine whose experience and dedication to the practice of medical and surgical oncology spans over 3 decades. There are very few types of cancer cases that we have not yet seen or treated. However, there are always new and challenging patients presented to us every day. I will periodically share more interesting cases, share with you ongoing updates on our clinical trials, and discuss novel therapies and ideas regarding the treatment of various cancers.

"Make no judgements where you have no compassion" .....Anne McCaffrey